发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. CD40 激动剂 MEDI5083 联合 durvalumab 治疗晚期实体瘤患者的 1 期研究。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-12 DOI: 10.1080/1750743x.2024.2359359
Ben Tran,Mark Voskoboynik,Johanna Bendell,Martin Gutierrez,Charlotte Lemech,Daphne Day,Sophia Frentzas,Ignacio Garrido-Laguna,Nathan Standifer,Fujun Wang,Charles Ferte,Yue Wang,Mayukh Das,Benedito A Carneiro
{"title":"A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.","authors":"Ben Tran,Mark Voskoboynik,Johanna Bendell,Martin Gutierrez,Charlotte Lemech,Daphne Day,Sophia Frentzas,Ignacio Garrido-Laguna,Nathan Standifer,Fujun Wang,Charles Ferte,Yue Wang,Mayukh Das,Benedito A Carneiro","doi":"10.1080/1750743x.2024.2359359","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2359359","url":null,"abstract":"Aim: This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors.Methods: Patients received MEDI5083 (3-7.5 mg subcutaneously every 2 weeks × 4 doses) and durvalumab (1500 mg every 4 weeks) either sequentially (N = 29) or concurrently (N = 9). Primary end point was safety; secondary end points included efficacy.Results: Thirty-eight patients received treatment. Most common adverse events (AEs) were injection-site reaction (ISR; sequential: 86%; concurrent: 100%), fatigue (41%; 33%), nausea (20.7%; 55.6%) and decreased appetite (24.1%; 33.3%). Nine patients had MEDI5083-related grade ≥3 AEs with ISR being the most common. Two patients experienced dose limiting toxicities (ISR). One death occurred due to a MEDI5083-related AE. MEDI5083 maximum tolerated dose was 5 mg. Objective response rate was 2.8% (1 partial response and 11 stable disease).Conclusion: MEDI5083 toxicity profile limits its further development.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"38 1","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiling of autoantibodies in the sera of glioblastoma patients. 分析胶质母细胞瘤患者血清中的自身抗体。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-12 DOI: 10.1080/1750743x.2024.2390350
Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu
{"title":"Profiling of autoantibodies in the sera of glioblastoma patients.","authors":"Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu","doi":"10.1080/1750743x.2024.2390350","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2390350","url":null,"abstract":"Aim: This study aimed to determine the expression pattern of autoantibody proteins from the serum of grade IV glioblastoma patients.Materials & methods: We performed high throughput antibody profiling via the Sengenics i-Ome® Protein Array to determine the differentially expressed autoantibodies.Results: The results portrayed that anti-COL4A3BP and anti-HSP90AA1 were among the upregulated autoantibodies in glioblastoma sera.Conclusion: The selected autoantibodies offer promising targets for future glioblastoma pathogenesis. However, further validation is required to elucidate the autoantibody signature in glioblastoma patients.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"42 1","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case reports of immune-related cystitis and the antibody combination hypothesis. 免疫相关性膀胱炎病例报告与抗体组合假说。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-12 DOI: 10.1080/1750743x.2024.2389761
Peng Zhang,Chunyan Yin,Ming Yang
{"title":"Case reports of immune-related cystitis and the antibody combination hypothesis.","authors":"Peng Zhang,Chunyan Yin,Ming Yang","doi":"10.1080/1750743x.2024.2389761","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2389761","url":null,"abstract":"Immune-related cystitis is a rare condition, and its diagnostic criteria and pathogenesis are not yet fully understood. Here, we report two cases of immune-related cystitis. Both patients were previously diagnosed with lung squamous cell carcinoma and received combined treatment with immune checkpoint inhibitors and chemotherapy, leading to hemorrhagic cystitis. We reviewed the cystoscopic images and pathological features of previous cases and found that autoantibodies against hemidesmosomes may be the cause of immune-related cystitis, proposing the \"antibody combination\" hypothesis to explain the tissue specificity of the condition.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"11 1","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity. 尼妥珠单抗加伊匹单抗辅助治疗期间的隐匿性检查点抑制剂心肌炎：一种隐匿但严重的毒性。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-11 DOI: 10.1080/1750743x.2024.2385286
Dimitrios Bafaloukos,Ioanna Gazouli,Aikaterini Bousmpoukea,Aristea Molfeta,Eleni Chatzichristou,George Samonis,Ioannis Vathiotis
{"title":"Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.","authors":"Dimitrios Bafaloukos,Ioanna Gazouli,Aikaterini Bousmpoukea,Aristea Molfeta,Eleni Chatzichristou,George Samonis,Ioannis Vathiotis","doi":"10.1080/1750743x.2024.2385286","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2385286","url":null,"abstract":"Checkpoint inhibitor myocarditis is a rare but life-threatening toxicity of immunotherapy, occasionally manifesting as persistent troponin elevation. Dual checkpoint blockade with ipilimumab and nivolumab has been found to induce immune-related myocarditis in patients with metastatic melanoma. We herein report a case of smoldering immune-related myocarditis in a 54-year-old male after a single infusion of nivolumab plus ipilimumab as adjuvant treatment for completely resected stage IV melanoma. High-dose steroid treatment resulted in decrease in the levels of cardiac enzymes, without any major complications.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"19 1","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report. 晚期胃癌超高龄患者对卡多尼单抗一线治疗的良好反应：病例报告。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-11 DOI: 10.1080/1750743x.2024.2394405
Jia Lun,Guikai Ma,Xuan Wang,Qian Wang
{"title":"Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report.","authors":"Jia Lun,Guikai Ma,Xuan Wang,Qian Wang","doi":"10.1080/1750743x.2024.2394405","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2394405","url":null,"abstract":"Gastric cancer remains a considerable global health burden, with limited treatment options available for advanced cases, especially for superaged patients. Cadonilimab, a first-in-class bi-specific antibody (BsAb), offer a promising immunotherapy approach by targeting PD-1/CTLA-4 simultaneously. Herein, we present a case report of an 85-year-old patient with HER2-negative advanced gastric cancer who received first-line treatment with cadonilimab combined with chemotherapy, but cadonilimab was discontinued due to the observation of immune-related pneumonitis during treatment. Despite these changes, the patient still exhibited a stable disease condition for a year until now. This case report highlights the potential of cadonilimab in the treatment of superaged patients with advanced gastric cancer, while the efficacy and safety of it need to be further evaluated.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"06 1","pages":"1-5"},"PeriodicalIF":2.8,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers? 免疫检查点抑制剂治疗转移性三阴性乳腺癌的前景如何？
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-30 DOI: 10.2217/imt-2024-0030
Ramon Andrade de Mello, Kátia Roque Perez, Puteri Abdul Haris
{"title":"What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?","authors":"Ramon Andrade de Mello, Kátia Roque Perez, Puteri Abdul Haris","doi":"10.2217/imt-2024-0030","DOIUrl":"https://doi.org/10.2217/imt-2024-0030","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease 利桑珠单抗在中重度克罗恩病治疗算法中的定位
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-17 DOI: 10.2217/imt-2023-0219
Francesca Lusetti, Ferdinando D'Amico, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese
{"title":"Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease","authors":"Francesca Lusetti, Ferdinando D'Amico, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese","doi":"10.2217/imt-2023-0219","DOIUrl":"https://doi.org/10.2217/imt-2023-0219","url":null,"abstract":"Risankizumab is a humanized monoclonal antibody that inhibits the p19 subunit of IL-23 cytokine. Recently it has been approved for the treatment of patients with moderate-to-severe Crohn's disease (CD). We conducted a scoping review to summarize the available data on risankizumab and to define its positioning in the treatment algorithm of CD. Pubmed, Embase and Scopus databases were searched up to Oct 31, 2023 to identify studies reporting efficacy and safety data of risankizumab in patients with CD. Risankizumab is an effective and safe drug for the management of patients with moderate-to-severe CD. It could be used as first-line therapy in biologic-naive patients and in patients who have previously failed other biological therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"19 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140611963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer 外周血中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值、泛免疫炎症值和全身免疫炎症指数对晚期胃癌患者免疫疗法疗效的预后价值
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-05 DOI: 10.2217/imt-2024-0031
Maodong Fu, Xiuping Zhang, Feng Shen, Jun Ma, Zhiyong Li
{"title":"Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer","authors":"Maodong Fu, Xiuping Zhang, Feng Shen, Jun Ma, Zhiyong Li","doi":"10.2217/imt-2024-0031","DOIUrl":"https://doi.org/10.2217/imt-2024-0031","url":null,"abstract":"Aim: The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) for predicting immunotherapy prognosis and efficacy in advanced gastric cancer (GC). Methods: A total of 84 advanced GC patients received immunotherapy were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, PIV and SII on patients prognosis. Results: NLR, PLR, PIV and SII had predictive value of efficacy. NLR ≥3.65 was an independent risk factor for worse outcomes. Conclusion: NLR, PLR, PIV and SII have predictive value of efficacy and NLR ≥3.65 suggests a poor prognosis following immunotherapy in advanced GC.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"50 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation-induced coronary artery disease during immune checkpoint inhibitor therapy: a case report. 免疫检查点抑制剂治疗期间辐射诱发的冠状动脉疾病：病例报告。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-05 DOI: 10.2217/imt-2023-0084
Xiajing Qian, Kequan Ding, Yi Lu
{"title":"Radiation-induced coronary artery disease during immune checkpoint inhibitor therapy: a case report.","authors":"Xiajing Qian, Kequan Ding, Yi Lu","doi":"10.2217/imt-2023-0084","DOIUrl":"10.2217/imt-2023-0084","url":null,"abstract":"<p><p>Radiation-induced coronary artery disease (RICAD) poses a serious concern for cancer patients post radiotherapy, typically emerging after over a decade. Immune checkpoint inhibitors (ICIs), known for cardiotoxicity, are increasingly recognized for causing cardiovascular complications. Here we report the case of a 63-year-old man with metastatic lung cancer who developed coronary artery disease during his third-line therapy with an ICI (nivolumab) and an antiangiogenic agent (bevacizumab), 3 years post chest radiotherapy. Angiography revealed relatively isolated stenosis in the left main coronary artery ostium, consistent with the radiotherapy site, with no other risk factors, suggesting RICAD. The potential for ICIs to accelerate RICAD development should be considered and necessitates careful surveillance in patients receiving both radiotherapy and ICIs.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"359-370"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic gastric cancer: synergizing and sequencing targeted therapy with first-line immunotherapy. 转移性胃癌：靶向治疗与一线免疫疗法的协同和排序。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-12 DOI: 10.2217/imt-2024-0040
Gina Colarusso, Hiba Mechahougui, Thibaud Koessler, Alex Friedlaender
{"title":"Metastatic gastric cancer: synergizing and sequencing targeted therapy with first-line immunotherapy.","authors":"Gina Colarusso, Hiba Mechahougui, Thibaud Koessler, Alex Friedlaender","doi":"10.2217/imt-2024-0040","DOIUrl":"10.2217/imt-2024-0040","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"427-430"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信